Life science researchers can explore new ideas for genome engineering technology through a newly announced post-doctoral research programme launched by Promega with mentoring support from AstraZeneca.

The programme gives researchers the unique opportunity to work on groundbreaking projects in an emerging field while collaborating with scientists at a global pharmaceutical company and a manufacturer of life science research tools.

Genome editing is a powerful tool for studying endogenous biology in physiologically relevant systems. With access to the genome editing capabilities of AstraZeneca and the bioluminescent reporter technology at Promega, these researchers will aim to develop new technologies for understanding and modulating cellular physiology in a multitude of clinically significant cellular backgrounds. Their work will support global efforts to detect, cure and treat disease.

Initially the researchers will collaborate to develop the technology recently published by Perterka et al., in Nature Communications to enable the highly efficient precise insertion of DNA sequences into the genome, expanding into other aspects of genome engineering as the projects progres.

The researchers will begin their work with the Genome Engineering team at the AstraZeneca R&D Center in Gothenburg, Sweden. They will later move to the Kornberg Center in Madison, Wisconsin to join the Advanced Technologies Group at Promega.